https://www.selleckchem.com/products/ca77-1.html
Peak-to-trough ratios in the repeated-dose study ranged from 1.3-1.4 with once-weekly dosing and 5.9-12.9 with once-monthly dosing. Following a single dose of efpeglenatide 14-100 μg/kg, FPG and PPG levels were decreased at week 1 and remained below baseline levels for ≥3 weeks post-dosing. Repeated doses of efpeglenatide led to significant reductions in HbA1c versus placebo. In both studies, efpeglenatide was generally well tolerated. Gastrointestinal disorders were the most frequently reported treatment-emergent adverse events in efpeg

https://www.selleckchem.com/pr....oducts/lomeguatrib.h
Busulfan and cyclophosphamide (BuCy) is a frequently used myeloablative conditioning regimen for allogeneic hematopoietic cell transplantation (allo-HCT). Theoretical considerations and pharmacological data indicate that application of busulfan prior to subsequent cyclophosphamide (BuCy) may trigger liver toxicity. Reversing the order of application to cyclophosphamide-busulfan (CyBu) might be preferable, a hypothesis supported by animal data and retrospective studies. We performed a prospective randomized trial to determine impact